Although KRAS G12C has been successful, numerous recurring oncoproteins and tumour suppressors, including MYC, β-catenin, and p53, have not been targeted with drugs. Additionally, resistance to single-drug treatments remains a significant obstacle. Recent technological advancements and novel strategies have started to tackle these obstacles, converting previously difficult-to-treat targets into ones that can be targeted with drugs. Some examples of these advancements include kinase inhibitors, antiapoptotic BCL2 proteins, and transcription factors. Innovations have dramatically influenced the growth in this field in structure-based design, chemically induced protein degradation, and targeted covalent inhibition ).